Genmab A-S

Yahoo Finance • 2 days ago

Major Shareholder Announcement

Genmab A/S Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; May 8, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis Investment M... Full story

Yahoo Finance • 3 days ago

DARZALEX royalties drive Genmab’s Q1 revenue higher amid expansion push

Investing.com -- Genmab reported a 25% year-on-year increase in first-quarter revenue for 2026, driven by strong royalty income from blockbuster cancer drug DARZALEX and multiple sclerosis treatment Kesimpta, as the Danish biotech company... Full story

Yahoo Finance • 3 days ago

Genmab Announces Financial Results for the First Quarter of 2026

Genmab A/S May 7, 2026 Copenhagen, Denmark; Interim Report for the Three Months Ended March 31, 2026 Highlights Genmab revenue increased25% compared to the first three months of 2025, to $896 million FDA approved an sBLA to remove the... Full story

Yahoo Finance • 8 days ago

Genmab (GMAB) Rated Outperform on Oncology Pipeline

Genmab A/S (NASDAQ:GMAB) ranks among the most profitable biotech stocks to buy now. Wolfe Research began coverage of Genmab A/S (NASDAQ:GMAB) on March 26 with a price objective of $32 and an Outperform rating. In anticipation of clinical t... Full story

Yahoo Finance • 16 days ago

Genmab A/S (GMAB) Rating Lifted by Goldman Sachs on Strong 2026 Catalyst Outlook

We recently compiled a list of the Top 10 AI-Powered Biotech Stocks to Buy Right Now. Genmab A/S  is among the best biotech stocks. TheFly reported on April 22 that The Goldman Sachs Group raised its rating on GMAB from Neutral to Buy and... Full story

Yahoo Finance • 26 days ago

Anthropic Adds Novartis CEO to Board

The startup behind the popular Claude chatbot and coding tool is eyeing a potential IPO as soon as this year. Continue Reading... Full story

Yahoo Finance • 26 days ago

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026

Company Announcement Net sales of DARZALEX® in the first quarter of 2026 totaled USD 3,964 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; Apri... Full story

Yahoo Finance • 27 days ago

Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer

Genmab A/S Media Release COPENHAGEN, Denmark; April 13, 2026 Phase 1/2 RAINFOL™-01 data showed the combination ofrinatabart sesutecan (Rina-S®) and bevacizumab was tolerable, with no new safety signals in patients with advanced ovaria... Full story

Yahoo Finance • last month

Wix downgraded, TripAdvisor upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Citi upgraded Bilibili (BILI) to Buy f... Full story

Yahoo Finance • 2 months ago

Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential?

On February 17, 2026, Paradigm Biocapital Advisors LP disclosed a buy of 750,000 shares of Olema Pharmaceuticals(NASDAQ:OLMA) in Q4 2025, an estimated $13.35 million trade based on quarter-end pricing. What happened According to a Securi... Full story

Yahoo Finance • 2 months ago

Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees in Genmab

Company Announcement COPENHAGEN, Denmark; March 19, 2026 – Genmab A/S (Nasdaq: GMAB) Following Genmab A/S’ Annual General Meeting held on March 19, 2026, the Company’s Board of Directors met to constitute itself. Ms. Deirdre P. Connelly... Full story

Yahoo Finance • 2 months ago

Passing of Genmab A/S’ Annual General Meeting

Company Announcement At Genmab A/S’ Annual General Meeting held today March 19, 2026, the Annual Report for 2025 was approvedDischarge was given to the Board of Directors and the Executive Management and the year’s profit was carried forw... Full story

Yahoo Finance • 2 months ago

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; March 2, 2026 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the t... Full story

Yahoo Finance • 2 months ago

Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; March 2, 2026 – Genmab A/S (Nasdaq: GMAB). On February 17, 2026, Genmab announced the initiation of a share buy-back program to repurchase up to 342,130 shares with a maximum aggregate total value... Full story

Yahoo Finance • 2 months ago

Bolt Biotherapeutics to Participate in Upcoming March Conferences

Bolt Biotherapeutics, Inc. REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announc... Full story

Yahoo Finance • 3 months ago

Novo Nordisk nominates three new board directors, two with pharma experience

[New Nordisk] hapabapa * Novo Nordisk has nominated Jan van de Winkel and Ramona Sequeira, both of whom have pharmaceutical industry experience, for its board. * Van de Winkel co-founded Genmab (GMAB [https://seekingalpha.com/symbol/... Full story

Yahoo Finance • 3 months ago

High Growth Tech Stocks To Watch In February 2026

As global markets navigate a landscape marked by AI disruption concerns and robust U.S. job gains, major indices like the Nasdaq Composite have experienced notable declines, reflecting broader market sentiment. Amidst this backdrop, identi... Full story

Yahoo Finance • 3 months ago

Genmab AS (GMAB) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansions

This article first appeared on GuruFocus. Total Revenue Growth: Increased by 19% to $3.7 billion in 2025. Operating Profit: Expanded to $1.26 billion in 2025. Sales of Proprietary Medicines: Totaled $632 million, up 54% year over year. Ab... Full story

Yahoo Finance • 3 months ago

Genmab Announces Initiation of Share Buy-Back Program

Genmab A/S Company Announcement Repurchase of up to 342,130 shares with a maximum aggregate total value of 725 million DKK Honoring our commitments under the Restricted Stock Unit program Completion expected no later than March 31, 2026... Full story

Yahoo Finance • 3 months ago

Genmab Publishes 2025 Annual Report

Company Announcement COPENHAGEN, Denmark; February 17, 2026 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2025. Below is a summary of business progress in 2025, financial performance for the year and... Full story